6533b7d6fe1ef96bd1266ecc
RESEARCH PRODUCT
Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia
Maciej BanachPeter P. TothPeter P. TothDragana NikolicJacek RyszManfredi Rizzsubject
Secondary preventionmedicine.medical_specialtyStatinBile acidbusiness.industrymedicine.drug_classmedicine.diseaseAppropriate useCoronary artery diseaseBile acid sequestrantMedicinelipids (amino acids peptides and proteins)businessIntensive care medicineDyslipidemiaLipoprotein cholesteroldescription
Lipid management guidelines promulgated around the world continue to emphasize the need to reduce serum levels of low-density lipoprotein cholesterol (LDL-C) in order to reduce risk for acute cardiovascular events in both the primary and secondary prevention settings [1–3]. There is growing consensus that when it comes to LDL-C management, lower is better with no apparent lower limit that is discernible from current evidence, i.e., there is greater and greater benefit as LDL-C decreases with no apparent loss in safety [4–8]. Dyslipidemia and coronary artery disease (CAD) are widely prevalent throughout the world. Considerable effort continues to be focused on expanding the appropriate use of lipid-lowering medication in order to more optimally reduce the burden of atherogenic lipoproteins in serum.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-01-01 |